Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs
Bullboard Posts
User Avatar Image
(625)
•••
Comment by KayakerBCon Jun 14, 2017 8:55pm
98 Views
Post# 26364227

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:biOasis CEO Dr. Mark Day Releases Details of Corporate Plans

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:biOasis CEO Dr. Mark Day Releases Details of Corporate PlansWhat do you make of this two years later given the additional delay now?

"Mr. Hutchison says biOasis is seeking patent protection around a Transcend-linked conjugate of Herceptin and plans to submit an IND in mid-2015 for human testing of the combination."

digitel, just for folks like yourself who seem to be out of the loop.  We now have a new CEO.  Yesterday BTI put out a NR where CEO MD explained priorities and programs going forward.  

I think it's pretty clear that the Herception IND wasn't submitted in 2015.  Progress for that and other programs hasn't lived up to expectations.  Are you just figuring that out now?

Anyhow, new CEO, new programs, new directions, new priorities.  Got it?  
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities